SCHEMBL2189252

SCHEMBL2189252

CC(C)(C1CCN(c2cc3ccccc3cn2)C(=O)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 4/20 0.44
CYP3A4 P08684 2/20 0.44
NR1I2 O75469 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
CTSS P25774 1/20 0.37
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
HSD11B1 P28845 1/20 0.36
CNR1 P21554 1/20 0.36
LMNA P02545 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2196073 0.88 CYP3A4 (0.46) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL7920460 0.88 CYP3A4 (0.46) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2189730 0.88 CYP3A4 (0.46) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2191324 0.87 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2189267 0.87 CYP3A4 (0.45) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2191587 0.87 CACNA1B (0.47) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2188544 0.86 CACNA1B (0.43) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2190754 0.86 CACNA1B (0.43) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2190115 0.86 CACNA1B (0.47) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E
SCHEMBL2189669 0.86 CACNA1B (0.49) CACNA1BCYP3A4NR1I2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.